New report covers challenges and opportunities in gene therapies

Gene therapies are being approved for use in Canada but could strain healthcare budgets and exacerbate existing treatment inequities across the country.

However, there are opportunities to control spending, streamline approvals, and support fair access through innovation, coordination and collaboration, according to a new expert panel report from the Council of Canadian Academies (CCA).

Rapid scientific advances mean potentially life-changing treatments are approaching the clinic at an accelerated pace. These new therapies, however, pose a number of challenges in terms of their introduction into the Canadian healthcare system and ensuring access to those who would most benefit."

Janet Rossant, PhD, CC, FRSC, and Chair of the Expert Panel

The National Research Council of Canada asked the CCA to examine the key legal, regulatory, ethical, social and policy challenges specific to the approval and use of somatic gene and engineered cell therapies in Canada.

Somatic gene and engineered cell therapies treat disease by removing or modifying existing genetic material in a patient, or introducing new genetic material, without passing these changes to future generations.

Most treat rare genetic disorders and cancers, however, they can cost more than $1 million and have limited evidence of long-term safety and durability.

From Research to Reality describes the stages involved in the approval and use of gene therapies in Canada, and examines the challenges associated with regulatory oversight, manufacturing, access, and affordability.

It also identifies emerging solutions that can capitalize on Canadian strengths in research, manufacturing, and health-care accessibility.

"The approval and use of gene therapies challenges payers, regulators, industry, patients, and families," said Eric M. Meslin, Ph.D., FCAHS, President and CEO of the CCA. "This report covers many of these challenges as well as possible paths forward, and will help to support evidence-informed decision making in Canada."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
You might also like... ×
Researchers investigate how brain's immune cells relate to a gene mutation in Alzheimer's disease